Findings
Verification and validation are crucial for ensuring the accuracy and precision of DHT measurements.
Not all PD manifestations are easily measurable by DHTs; some require in-person assessments.
There is inconsistency in outcomes measured and methods of assessing validity.
Many DHT measurements are still in early research stages and need larger sample sizes.
Shortfalls in sensor specificity suggest a need for multiple measurement modalities.

Recommendations
Use multiple modalities of measurement to improve specificity.
Engage patients early to determine relevant endpoints for functional measurements.
Ensure DHTs are user-friendly and safe for participants.
Conduct randomized and blinded trials to confirm sensor effectiveness.
Consider decentralized trials to facilitate participation for patients with mobility challenges.

Regulatory Considerations
Ensure safety and welfare of subjects through FDA regulations.
Randomized and blinded trials are essential for confirming sensor-detected effects.
Decentralized trials can improve participation by overcoming mobility challenges.